8-K: Cerus Corporation Reports 24% Increase in First Quarter Product Revenue, Reaffirms Full-Year Guidance

Cerus Corporation announced a 24% year-over-year increase in product revenue for the first quarter of 2024, driven by strong sales of its INTERCEPT Blood System for Platelets.

Summary

• Cerus Corporation reported a 24% increase in product revenue for the first quarter of 2024, reaching $38.4 million, compared to $31.0 million in the same period last year.
• The company's total revenue for the quarter was $43.4 million, a 13% increase from $38.5 million in the first quarter of 2023.
• Government contract revenue decreased by 33% to $5.0 million, primarily due to the completion of the U.S. Phase 3 ReCePI clinical trial for INTERCEPT RBCs.
• The company's product gross profit increased by 23% to $21.3 million, with a stable gross margin of 55.4%.
• Operating expenses decreased by 12% to $34.3 million, driven by cost optimization efforts and restructuring.
• Net loss attributable to Cerus Corporation improved to $9.7 million, or $0.05 per share, compared to a net loss of $15.6 million, or $0.09 per share, in the first quarter of 2023.
• Non-GAAP adjusted EBITDA was negative $2.7 million, an improvement from negative $9.8 million in the same period last year.
• Cerus is reiterating its full-year 2024 product revenue guidance of $172 million to $175 million, including $8 million to $10 million from INTERCEPT Fibrinogen Complex.
• The company expects to achieve adjusted EBITDA breakeven for the full year 2024, while still anticipating a GAAP net loss.
• Cash and cash equivalents and short-term investments totaled $72.2 million at the end of the quarter.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, successful clinical trial results, and improved financial performance. The company is on track to meet its full-year guidance and achieve adjusted EBITDA breakeven. However, the company still anticipates a GAAP net loss and faces some risks, which prevents a perfect score.

Positives

• Product revenue saw a significant 24% increase year-over-year, indicating strong sales performance.
• The successful completion of the ReCePI trial is a major milestone for the INTERCEPT Red Blood Cell program.
• The extended shelf life approval for platelet processing sets is expected to positively impact future revenue.
• Operating expenses decreased by 12%, showing effective cost management.
• The company generated positive operating cash flow of $2.0 million, a significant improvement from the previous year.
• The company is on track to achieve adjusted EBITDA breakeven for the full year 2024.
• North American platelet kit sales grew by 44% year-over-year, demonstrating strong regional performance.

Negatives

• Government contract revenue decreased by 33% due to the completion of the ReCePI trial.
• The company still anticipates a GAAP net loss for the full year 2024.
• Non-GAAP adjusted EBITDA was still negative at $2.7 million for the quarter.

Risks

• The company faces risks associated with the commercialization and market acceptance of the INTERCEPT Blood System.
• Macroeconomic developments, including military conflicts and the COVID-19 pandemic, could negatively impact the business.
• There are risks related to the development and regulatory process for new products, including the INTERCEPT RBCs.
• The company relies on third parties for manufacturing, marketing, and distribution, which introduces supply chain risks.
• The company needs to access additional funds under its credit facility and may require additional funding in the future.
• There are risks related to future opportunities and plans, including the uncertainty of future capital requirements and financial performance.

Future Outlook

Cerus is reiterating its full-year 2024 product revenue guidance of $172 million to $175 million and expects to achieve adjusted EBITDA breakeven for the full year 2024, while still anticipating a GAAP net loss. The company is also targeting a commercial launch of its LED illuminator program in the EU in 2025.

Management Comments

• The Cerus team delivered against our plans for Q1, paving the way for the balance of 2024, with great progress on clinical milestones and a strong return to growth for our commercial business.
• The positive topline readout from ReCePI, the U.S. Phase 3 clinical trial for INTERCEPT Red Blood Cells, is a significant milestone for the program and for our efforts to potentially bring this product to the market globally.
• We are also on track for our expectations to post double-digit product revenue growth this year.
• Now a third of the way through 2024, we are increasingly confident in our full-year product revenue growth trajectory.

Industry Context

The announcement reflects a positive trend in the blood transfusion industry, with increased adoption of pathogen reduction technologies. Cerus's growth is driven by its INTERCEPT Blood System, which is gaining traction in North America and other regions. The extended shelf life approval for platelet processing sets is a significant development that could further enhance the company's competitive position.

Comparison to Industry Standards

• Cerus's 24% product revenue growth is strong compared to some of its competitors in the blood products industry, although direct comparisons are difficult due to varying product portfolios and market focus.
• Companies like Haemonetics and Terumo BCT also operate in the blood component and technology space, but their financial results and product focus differ from Cerus.
• The successful completion of the ReCePI trial and the extended shelf life approval are significant achievements that position Cerus well against competitors in the pathogen reduction market.
• The company's focus on achieving adjusted EBITDA breakeven is a key goal, as many biotech companies in the development stage often struggle with profitability.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved financial performance positively.
• Employees may be encouraged by the company's progress and future prospects.
• Customers, including blood centers and hospitals, will benefit from the extended shelf life of platelet processing sets and the potential availability of INTERCEPT Red Blood Cells.
• Suppliers will continue to play a crucial role in the company's supply chain.
• Creditors will be reassured by the company's improved cash flow and commitment to debt service obligations.

Next Steps

• Continue commercialization efforts for the INTERCEPT Blood System.
• Advance the LED illuminator program towards commercial launch in the EU in 2025.
• Focus on achieving positive operating cash flows for the balance of 2024.
• Pursue regulatory approvals for INTERCEPT Red Blood Cells in Europe and the US.
• Continue to expand the INTERCEPT Fibrinogen Complex business.

Key Dates

Keywords

INTERCEPT Blood System, Pathogen Reduction, Platelets, Plasma, Red Blood Cells, Fibrinogen Complex, FDA Approval, Clinical Trial, Revenue Growth, EBITDA, Blood Transfusion, Healthcare